Logo
homeHome
toggle_offCompany ProfilegroupsBoards & Staffsworkspace_premiumMemberships & PartnersschoolAcademy of Journalismperson_addCareerslinkBlog(EN)emailContact Us
list_altOur JournalslightbulbInstruction for AuthorsbookmarkBrieflands PolicieshandshakePublish My Researchplay_circleJournal Management Systemcredit_cardArticle Processing Chargeszoom_inOpen Peer ReviewimagePublishing Services
menu_bookPublish My Book
  1. Brieflands
  2. journals
  3. Hepatitis Monthly
  4. Articles

  5. The ITPA and C20orf194 Polymorphisms and Hematological Changes During Treatment With Pegylated-Interferon Plus Ribavirin in Patients With Chronic Hepatitis C
  6. Scopus by Title (Ref)

Hepatitis Monthly

Official Journal of Research Center for Gastroenterology and Liver Diseases

homeHome
play_circleCurrent Issuecheck_circleAccepted ManuscriptslistAll Issuesformat_indent_increaseIn Press ArticlessearchSearch
helpInstructions
infoJournal InformationgroupsBoards and committeesshareIndexing and Listing Sourcesshow_chartJournal Metricszoom_inOpen Peer Review (OPR)balancePublication Ethics and Malpractice Statementmenu_bookReviewer and AE Registration FormemailSupportphoneContact Us
format_list_bulletedAPC
Authors GuideSubmit Manuscript

Scopus by Title (Ref)


1. Protective role of ITPA rs1127354-CA polymorphism against anemia in HCV patients using sofosbuvir ribavirin therapy: age and gender match case-control study

- Amjed S. , et al.

2. Inosine triphosphate pyrophosphatase polymorphisms are predictors of anemia in Chinese patients with chronic hepatitis C during therapy with ribavirin and interferon

- Chi X. , et al.

3. A facile PCR-RFLP method for genotyping of ITPA rs1127354 and rs7270101 polymorphisms

- Alavian S. , et al.

4. The role of polymorphisms near IFNL3 gene as predictors of residual HCV RNA in buffy coat after successful antiviral therapy

- Miri S.M. , et al.

5. A simple PCR-RFLP method for genotyping of IFNL4 rs368234815 polymorphism in patients with chronic hepatitis C

- Pouryasin M. , et al.

6. Double therapy with pegylated interferon and ribavirin for chronic hepatitis C. A pharmacogenetic guide for predicting adverse events

- Kamal A. , et al.

HomeInstructionsAPC

Articles

  • Current Issue
  • Accepted Manuscripts
  • All Issues
  • In Press Articles
  • Search

About Journal

  • Journal Information
  • Boards and committees
  • Indexing and Listing Sources
  • Journal Metrics
  • Open Peer Review (OPR)
  • Publication Ethics and Malpractice Statement
  • Reviewer and AE Registration Form
  • Support
  • Contact Us
Support
Submit a Ticket
BrieflandsBrieflands

Science, Technical, Medical Publisher, Since 2007

All rights reserved by Brieflands, 2026.

Powered by Neoscriber.